4/ By introducing each target to the right DUB, ENTACs enhance the function of these crucial proteins — many of which cannot be targeted with existing drugs — ultimately restoring the cell’s health.
Learn more about our science: https://t.co/ZLMKwVOC6Y
3/ Whether the target protein:
☑️ is in short supply
☑️ is in the wrong place within the cell
☑️ has suboptimal activity
…an ENTAC can be designed to recruit a DUB to fix the problem.
Welcoming some new faces at Entact!👋
We’re excited to have Fiona O'Brien, Rami Taha, and Micco Iwase join us as co-ops from @Northeastern.
We can’t wait to see their fresh perspectives and enthusiasm in action. Stay tuned for more! 🎉
2/ By recruiting the right DUB for each target, ENTACs harness the natural ability of DUBs to enhance protein function.
Learn more on our website: https://t.co/Vj1xXk8DJp
1/ Most drugs inhibit proteins that contribute to disease. What if we could instead enhance proteins that restore health?
At Entact we’re doing just that. Our drugs, called ENTACs, are molecular matchmakers, bringing together target proteins with enzymes called DUBs.
Our unique approach to drug discovery is driven by the question: What if we could enhance proteins that restore health, rather than inhibiting proteins that cause disease?
Hear more from founder Sara Buhrlage and the Entact team: https://t.co/vifpWDJ1Wf
Earlier this month we took a quick break from our pursuit of novel drug targets and took aim at a different type of target: a high-tech, auto-scoring dartboard 🎯
One discovery: Some Entackers have clearly thrown a dart or two in their day!
#biotech#startups
4/ Off duty, Tom’s a committed Celtics fan and father of two, including a three-year-old budding scientist!
Discover your role at Entact, working alongside Tom to build much-needed new medicines: https://t.co/37N1wYQi6a
1/ Thrilled to highlight Tom Blaisdell, Principal Scientist on the Molecular Discovery team in our #EmployeeSpotlight. Following his passion for #chemistry from the lab to #biotech, his expertise in structure-based molecular design is critical to Entact's drug discovery approach.
3/ As chemistry lead on several projects, Tom has a unique ability to present data in highly visual and accessible ways that foster interdisciplinary collaboration across teams.
2/ Mike brings with him over two decades of industry experience, including leadership roles spanning operations, finance, and business development at global pharmaceutical companies, clinical-stage biotechs, and life science venture capital firms
ICYMI our CEO Vicky Richon joined the Discovery Matters Podcast to discuss how Entact is tackling challenging diseases with targeted protein enhancement.
Check out the full episode 👉
https://t.co/3bC1iqjiLz
Great story by @GabrielleMasso9 at @FierceBiotech highlighting takeaways from the recent summit hosted by the #BiotechSisterhood, a group of women leaders in the industry including our CEO, Victoria Richon.
Read more 👉 https://t.co/Z2m39g7pVM
We’re hiring! Join us to help expand the universe of treatable diseases.
Check out these open roles! 👇
Principal Scientist - Medicinal Chemistry
https://t.co/39bpeeqpBL
Principal Scientist/Associate Director – Proteomics
https://t.co/FNemXYzJDx
#biotech#drugdevelopment
At Entact, we’re building a dedicated team of biologists, chemists, biochemists, and crystallographers passionate about developing new solutions for patients. Hear insights from our CEO Victoria Richon and our scientific founders. https://t.co/vifpWDJ1Wf (1/2)